View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 30, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	0001107421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ZIOP
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		162,394,494

BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 51,487	$ 61,729
Receivables	854	1,864
Prepaid expenses and other current assets	21,752	20,692
Total current assets	74,093	84,285
Property and equipment, net	967	1,097
Operating lease right of use assets	1,589
Deposits	130	128
Other non-current assets	6,724	9,541
Total assets	83,503	95,051
Current liabilities:
Accounts payable	859	707
Accrued expenses	6,836	8,763
Lease liability - current portion	644
Deferred rent - current portion		13
Total current liabilities	8,339	9,483
Lease liability - noncurrent portion	948
Deferred rent - noncurrent portion		4
Total liabilities	9,287	9,487
Commitments and contingencies (Note 6)
Stockholders' deficit:
Common stock, $0.001 par value; 250,000,000 shares authorized; 162,287,161 and 161,066,136 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	162	161
Additional paid-in capital	653,817	651,732
Accumulated deficit	(579,763)	(566,329)
Total stockholders' equity	74,216	85,564
Total liabilities and stockholders' equity	$ 83,503	$ 95,051

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	162,287,161	161,066,136
Common stock, shares outstanding	162,287,161	161,066,136

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Collaboration revenue		$ 146
Operating expenses:
Research and development	$ 9,476	10,183
General and administrative	4,145	6,159
Total operating expenses	13,621	16,342
Loss from operations	(13,621)	(16,196)
Other income, net	187	148
Change in fair value of derivative liabilities		28
Net loss	(13,434)	(16,020)
Preferred stock dividends		(5,120)
Net loss applicable to common stockholders	$ (13,434)	$ (21,140)
Basic and diluted net loss per share	$ (0.08)	$ (0.15)
Weighted average common shares outstanding used to compute basic and diluted net loss per share	160,640,859	140,853,120

STATEMENTS OF CHANGES IN PREFERRED STOCK AND STOCKHOLDERS' Equity (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital Common Stock	Accumulated Deficit	Series 1 Preferred Stock - Mezzanine
Balance at Dec. 31, 2017	$ (96,806)	$ 143	$ 615,493	$ (712,442)	$ 143,992
Balance (in shares) at Dec. 31, 2017		142,658,037			119,644
Adjustment for implementation of ASU No. 2014-09, Revenue from Contracts with Customers	(8,131)			(8,131)
Stock-based compensation	3,659		3,659
Cancelled restricted common stock (in shares)		(70,867)
Repurchase of restricted common stock	(731)	$ (1)	(730)
Repurchase of restricted common stock (Shares)		(188,234)
Preferred stock dividends					$ 5,047
Preferred stock dividends	(5,120)		(5,120)
Preferred stock dividends (in shares)					3,624
Net loss	(16,020)			(16,020)
Balance at Mar. 31, 2018	(123,149)	$ 142	613,302	(736,593)	$ 149,039
Balance (in shares) at Mar. 31, 2018		142,398,936			123,268
Balance at Dec. 31, 2018	85,564	$ 161	651,732	(566,329)
Balance (in shares) at Dec. 31, 2018		161,066,136
Stock-based compensation	1,456		1,456
Issuance of restricted common stock	1,000	$ 1	999
Issuance of restricted common stock (in shares)		1,393,536
Cancelled restricted common stock (in shares)		(7,333)
Repurchase of restricted common stock	(370)		(370)
Repurchase of restricted common stock (Shares)		(165,178)
Net loss	(13,434)			(13,434)
Balance at Mar. 31, 2019	$ 74,216	$ 162	$ 653,817	$ (579,763)
Balance (in shares) at Mar. 31, 2019		162,287,161

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (13,434)	$ (16,020)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	140	117
Stock-based compensation	1,456	3,659
Bonus paid in common stock, net	630
Change in fair value of derivative liabilities		(28)
(Increase) decrease in:
Receivables	1,009	1
Prepaid expenses and other current assets	(1,058)	(1,172)
Other noncurrent assets	2,817	(490)
Deposits	(2)
Increase (decrease) in:
Accounts payable	152	(3,811)
Accrued expenses	(1,929)	(1,030)
Deferred revenue		(146)
Deferred rent	17	(37)
Other liabilities	(30)
Net cash used in operating activities	(10,232)	(18,957)
Cash flows from investing activities:
Purchases of property and equipment	(10)	(150)
Net cash used in investing activities	(10)	(150)
Cash flows from financing activities:
Repurchase of common stock		(731)
Net cash provided by (used in) financing activities	0	(731)
Net decrease in cash and cash equivalents, and restricted cash	(10,242)	(19,838)
Cash and cash equivalents, and restricted cash, beginning of period	61,729	71,335
Cash and cash equivalents, and restricted cash, end of period	51,487	51,497
Supplementary disclosure of cash flow information:
Bonus paid in common stock, gross	$ 1,000
Series 1 Preferred Stock
Supplementary disclosure of noncash investing and financing activities:
Payment of dividends in preferred stock		$ 5,120

Business

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Business

1. Business

Overview

ZIOPHARM Oncology, Inc., which is referred to herein as “ZIOPHARM,” or the “Company,” is a biopharmaceutical company seeking to develop, acquire, and commercialize, on its own or with partners, a diverse portfolio of immuno-oncology therapies.

The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31.

The Company has operated at a loss since its inception in 2003 and has no recurring revenues from operations. The Company anticipates that losses will continue for the foreseeable future. As of March 31, 2019, the Company had approximately $51.5 million of cash and cash equivalents and the Company’s accumulated deficit was approximately $579.8 million. Given its current development plans, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2020.

The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash.

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations.

It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2018, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 5, 2019, or the Form 10-K.

The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States.

The results disclosed in the statements of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the full fiscal year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

The Company’s most significant estimates and judgments used in the preparation of its financial statements are:

•

Clinical trial expenses;

•

Collaboration agreements and revenue recognition;

•

Fair value measurements of stock based compensation and Series 1 preferred stock; and

•

Income taxes

Subsequent Events

The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any material subsequent events that impacted its financial statements or disclosures.

On December 18, 2018, Ziopharm and TriArm Therapeutics, Ltd. (“TriArm”) announced that the companies plan to launch Eden BioCell, Ltd. (“Eden BioCell”) to lead clinical development and commercialization of

Sleeping Beauty

-generated CAR-T therapies in the People’s Republic of China (including Macau and Hong Kong), Taiwan and Korea. TriArm is a cell therapy company with operations in Germany, China and the United States.

For the territory of China, Taiwan and Korea, Ziopharm will license the rights to Eden BioCell for third-generation

Sleeping Beauty

-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell will be jointly-owned by Ziopharm and TriArm. TriArm has committed up to $35.0 million to this joint venture. Under the terms of the agreement, Eden BioCell has rights in the region to CAR-T cells very rapidly manufactured in two days or less using the

Sleeping Beauty

platform to express a CD19-specific CAR and membrane-bound interleukin 15, or mbIL15, along with a kill switch. Each party will share decision-making authority. TriArm will manage all clinical development to execute trials in China for Eden BioCell. On January 3, 2019 Eden BioCell was incorporated in Hong Kong. The definitive agreements are expected to be executed in the first half of 2019.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies were identified in the Company’s Form 10-K. There have been no material changes in those policies since the filing of its Form 10-K except as noted below with respect to the Company’s revenue recognition.

Leases

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by requiring the recognition of a right-of-use assets and lease liabilities for most lease arrangements on the balance sheet. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for fiscal years beginning after December 15, 2018, and the Company adopted the standard on January 1, 2019.

The standard permits two transition methods, (1) to apply the new lease requirements at the beginning of the earliest period presented, or (2) to apply the new lease requirements at the effective date. Under both transition methods there is a cumulative effect adjustment. The Company adopted Topic 842 as of January 1, 2019 using the effective date method, in which it did not restate prior periods. Upon adoption, the Company elected the package of practical expedients permitted under the transition guidance within Topic 842 which, among other things, allowed it to carry forward the historical lease classification.

The adoption of Topic 842 resulted in recognition of approximately

$1.6

million of right-of-use assets and

$1.6

million of lease liabilities on the Company’s balance sheets. The adoption did not have a material impact on the Company’s statements of operations or accumulated deficit. The Company has implemented changes to related processes, controls and disclosures in connection with the adoption of Topic 842 (Note 8).

New Accounting Pronouncements

In November 2016, the FASB issued ASU 2016-18,

Statement of Cash Flows: Restricted Cash

or ASU 2016-18. The amendments in this update require that amounts generally described as restricted cash and restricted cash equivalents be included within cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 was effective January 1, 2018. As a result of adopting ASU 2016-18, the Company includes its restricted cash balance in the cash and cash equivalents reconciliation of operating, investing and financing activities. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows.

		March 31,
	2019		2018
	(in thousands)
Cash and cash equivalents	$	51,487		$	51,108
Restricted cash included in prepaid expenses and other current assets		—			389
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	51,487		$	51,497

In August 2018, the FASB issued ASU No. 2018-13,

Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

, or ASU 2018-03. The guidance in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Under the new guidance, transfers between asset classes and the valuation related to level 3 assets is modified. The new standard is effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within each annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on the financial statements.

In June 2018, the FASB issued ASU No. 2018-07,

Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

, or ASU 2018-07. The guidance in this ASU expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard is effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within each annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on the financial statements.

Fair Value Measurements

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value on a recurring basis as of March 31, 2019 and December 31, 2018 were as follows:

($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of March 31, 2019		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	24,568	$	24,568	$	—	$	—

($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of December 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	24,437	$	24,437	$	—	$	—

The cash equivalents represent deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.

Net Loss per Share

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss per Share

4. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potentially dilutive shares of common stock at March 31, 2019 and 2018 consisted of the following:

	March 31,
	2019		2018
Stock options		5,416,085		3,822,968
Unvested restricted stock		1,621,845		1,532,201
Warrants		18,939,394		—
Preferred stock		—		35,152,089
		25,977,324		40,507,258

During the year ended December 31, 2018, the Company and Precigen, Inc., or Precigen, a wholly owned subsidiary of Intrexon Corporation, or Intrexon, entered into a License Agreement to replace all existing agreements between the companies that will provide the Company with certain exclusive and non-exclusive rights to technology controlled by Precigen. The License Agreement was dated October 5, 2018. In consideration of the Company entering into the License Agreement, Intrexon agreed to forfeit and return to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement (Note 6).

Revenue Recognition

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

Revenue Recognition

5. Revenue Recognition

The Company adopted Accounting Standards Codification, or ASC Topic 606,

Revenue from Contracts with Customers,

or ASC 606, using the modified retrospective approach on January 1, 2018. The Company completed its assessment and the implementation resulted in a cumulative effect adjustment to accumulated deficit as of January 1, 2018 of approximately $8.1 million and a corresponding increase to the contract liability (formerly deferred revenue). The adjustment to the Company’s financial statements due to the adoption of ASC 606

is related to the Company’s License and Collaboration Agreement with Ares Trading S.A., a subsidiary of Merck KGaA, or the Ares Trading Agreement, (Note

6), which was the Company’s sole open revenue contract outstanding at January 1, 2018.

The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, the Company recognized revenue in accordance with ASC 606 which replaced ASC 605,

Multiple Element Arrangements

, as used in historical years. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied.

The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Contracts that include an option to acquire additional goods and/or services are evaluated to determine if such option provides a material right to the customer that it would not have received without entering into the contract. If so, the option is accounted for as a separate performance obligation. If not, the option is considered a marketing offer which would be accounted for as a separate contract upon the customer’s election.

The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front payment, (ii) development, regulatory and commercial milestone payments, (iii) future options and (iv) royalties on net sales of licensed products. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the most likely amount method to estimate the amount of variable consideration, to predict the amount of consideration to which it will be entitled for its one open contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered probable of achievement and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Company or the licensee, such as those dependent upon receipt of regulatory approval, are not considered to be probable of achievement until the triggering event occurs. At the end of each reporting period, the Company reevaluates the probability of achievement of each milestone and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. For arrangements that include sales-based royalties, including milestone payments based upon the achievement of a certain level of product sales, the Company recognizes revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any development, regulatory or commercial milestones or royalty revenue resulting from any of its collaboration arrangements. Consideration that would be received for optional goods and/or services is excluded from the transaction price at contract inception.

The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgment to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success.

Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment.

As it relates to the Ares Trading Agreement (Note 6), the Company recognized the upfront payment associated with its one open contract as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified in current liabilities. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as contract liabilities, net of current portion. The Company determined that there were three performance obligations; the first performance obligation consists of the license and research development services and the other two performance obligations are material rights as it relates to potential future targets that have not yet been identified. As described above, the transaction price of $57.5 million was allocated to the performance obligations based on their relative standalone selling

prices (see Note 6).

There are multiple distinct performance obligations, including material rights; thus, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost-plus margin. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. Furthermore, the Company has not capitalized any contract costs under the guidance in ASC 340-40,

Other Assets and Deferred Costs: Contracts with Customers

The Company does not believe that any variable consideration should be included in the transaction price at the date of adoption of ASC 606 on January 1, 2018. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as other changes in circumstances occur.

On October 5, 2018, the Company entered into the license agreement with Precigen. As between the Company and Precigen, the terms of the License Agreement replace the terms of: (a) the Channel Agreement previously entered into with Intrexon Corporation (the “Channel Agreement”), including all amendments to the Channel Agreement; (b) certain rights and obligations pursuant to the Ares Trading Agreement; (c) the MD Anderson License (Note 6); and (d) that certain Research and Development Agreement between the Company, Intrexon and The University of Texas MD Anderson Cancer Center, or MD Anderson, with an effective date of August 17, 2015 or the Research and Development Agreement, and any amendments or statements of work thereto.

partial consideration of the Company entering into the License Agreement, Precigen is required to use diligent good faith efforts to transfer the Company’s rights and obligations under the Ares Trading Agreement to Intrexon (or it’s affiliate). As a result, the Company has very limited obligations under the Ares Trading Agreeme

nt.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. Commitments and Contingencies

License Agreements

Exclusive License Agreement with Precigen, Inc.

On October 5, 2018, the Company entered into an exclusive license agreement, or the License Agreement, with Precigen. As between the Company and Precigen, the terms of the License Agreement replace and supersede the terms of: (a) that certain Exclusive Channel Partner Agreement by and between the Company and Intrexon, dated January 6, 2011, as amended by the First Amendment to Exclusive Channel Partner Agreement effective September 13, 2011, the Second Amendment to the Exclusive Channel Partner Agreement effective March 27, 2015, and the Third Amendment to Exclusive Channel Partner Agreement effective June 29, 2016, which was subsequently assigned by Intrexon to Precigen; (b) certain rights and obligations pursuant to that certain License and Collaboration Agreement effective March 27, 2015 between

ZIOPHARM

, Intrexon and ARES TRADING S.A., or Ares Trading, a subsidiary of Merck KGaA, or Merck, as assigned by Intrexon to Precigen, or the Ares Trading Agreement; (c) that certain License Agreement between the Company, Intrexon, and MD Anderson, with an effective date of January 13, 2015, or the MD Anderson License, which was subsequently assigned by Intrexon and assumed by Precigen effective as of January 1, 2018; and (d) that certain Research and Development Agreement between the Company, Intrexon and MD Anderson with an effective date of August 17, 2015, or the Research and Development Agreement, and any amendments or statements of work thereto.

Pursuant to the terms of the License Agreement, Precigen has granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing Precigen’s RheoSwitch® gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products, (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) a second target, subject to the rights of Merck to pursue such target under the Ares Trading Agreement, and (iii) TCR products designed for neoantigens for the treatment of cancer. Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the

Sleeping Beauty

technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.

The Company will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts to develop and commercialize IL-12 products and CD19 products and after a two-year period, the TCR Products.

Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 for the treatment of cancer, referred to as Gorilla IL-12 Products.

In consideration of the licenses and other rights granted by Precigen, the Company will pay Precigen an annual license fee of $0.1 million and has agreed to reimburse Precigen for certain historical costs of the licensed programs up to $1.0 million, payable quarterly.

The Company will make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay Precigen tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 products and CAR products. The Company will also pay Precigen royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR Products, up to a maximum royalty amount of $

100

.0 million in the aggregate. The Company will also pay Precigen

% of any sublicensing income received by the Company relating to the licensed products.

The Company is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 products. The Company and Precigen will share the development costs and operating profits for Gorilla IL-12 products, with the Company responsible for 80% of the development costs and receiving 80% of the operating profits, and Precigen responsible for the remaining 20% of the development costs and receiving 20% of the operating profits.

Precigen will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of Precigen’s CAR products, up to $50.0 million.

In consideration of entering into the License Agreement, Intrexon has forfeited and returned to the Company all shares of Series 1 preferred stock held by or payable to Intrexon as of the date of the License Agreement (Note 7).

License Agreement—The University of Texas MD Anderson Cancer Center

On January 13, 2015, the Company, together with Intrexon, entered into the MD Anderson License with MD Anderson (which Intrexon subsequently assigned to Precigen). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who became the Company’s Chief Executive Officer in

May 2015

and was formerly a tenured professor of pediatrics at MD Anderson and is now currently a visiting scientist under that institution’s policies.

On August 17, 2015, the Company, Precigen and MD Anderson entered into the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs.

Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson formed a joint steering committee to oversee and manage the new and ongoing research programs. Under the License Agreement with Precigen, the Company and Precigen agreed that Precigen would no longer participate on the joint steering committee after the date of the License Agreement. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than

$15.0 million and no greater than $20.0 million per year. On November 14, 2017, the Company entered into an amendment to the Research and Development Agreement extending its term until April 15, 2021. During the three months ended March 31, 2019, the Company expensed approximately $1.4 million for its research programs being conducted in Houston. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $

26.4

million, of which $19.8 million is included in other current assets and the remaining $6.6 million is included in non-current assets at March 31, 2019.

The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-

day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.

Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute

On January 10, 2017, the Company announced the signing of a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI for the development of adoptive cell transfer, or ACT,-based immunotherapies genetically modified using the

Sleeping Beauty

transposon/transposase system to express TCRs for the treatment of solid tumors. The principal goal of the CRADA is to develop and evaluate ACT for patients with advanced cancers using autologous peripheral blood lymphocytes, or PBL, genetically modified using the non-viral

Sleeping Beauty

system to express TCRs that recognize neoantigens expressed within a patient’s cancer. Research conducted under the CRADA will be at the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company’s researchers.

In February 2019, the Company extended the CRADA with the NCI for two years, committing an additional $5.0 million to this

program through January 2022. The

remaining obligation, as of March 31, 2019, to the

NCI under the CRADA is

$6.9 million over the next two years, payable in $625 thousand payments on a quarterly basis. The Company made one payment of $625 thousand, during the three months ended March 31, 2019 and 2018, respectively.

Exclusive Channel Partner Agreement with Precigen for the Cancer Programs

From 2011 to 2018, the Company was party to various arrangements with Intrexon (now Precigen) in which the Company used Precigen’s technology to research and develop cancer treatments in return for various future profit sharing and royalty arrangements. These agreements were modified or terminated by the License Agreement described in Note 7.

Ares Trading License and Collaboration Agreement

On March 27, 2015,

the Company, together with Intrexon (now Precigen), signed the Ares Trading Agreement, with Ares Trading, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans.

Precigen was entitled to receive $5.0 million, from Ares Trading, payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company was responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. For the three months ended March 31, 2018, the Company expensed $1.6 million under the Ares Trading Agreement. The Company did not incur any costs under the agreement for the three months ended March 31, 2019 as there are no continuing obligations to reimburse

Precigen for expenses under the Ares Trading Agreement following the October 2018 license.

Ares Trading paid a non-refundable upfront fee of $115.0

million to Intrexon as consideration for entry into the Ares Trading Agreement. Pursuant to the Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, the Company was entitled to receive

50% of the upfront fee, or $57.5 million, which was received from Intrexon in July 2015.

Under the License Agreement, Precigen agreed to perform all future obligations of the Company under the Ares Trading Agreement other than certain payment obligations. Accordingly, the Company recognized the remaining deferred revenue as part of the settlement of related party relationships as described in Note 7.

Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System

On August 24, 200

the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.

The Company issued options to purchase 50,222 shares outside of its stock option

plans. The options vested upon completion of certain clinical milestones, all of which have occurred and the options are now fully vested. An expense of

$87

thousand was charged to research and development expense for the final vesting event which occurred in March 2016 upon enrollment of the first patient in a multi-center pivotal clinical trial

i.e.

a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable New Drug Application, or NDA. This trial was initiated by Solasia Pharma K.K., or Solasia, on March 28, 2016 and triggered a

$1.0

million milestone payment to the Company from Solasia which was received in May 2016. An equivalent

$1.0

million milestone payment was subsequently made to MD Anderson and reported net. In addition, the Company may be required to make additional payments to the Licensors upon achievement of certain other milestones in varying amounts which, on a cumulative basis could total up to an additional

$4.5

million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances.

Collaboration Agreement with Solasia Pharma K.K.

On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific territory comprising Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.

As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. The $5.0 million upfront payment received in March 2011 was amortized over the period of the research and development effort, which was completed in March 2016.

On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia.

Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the license agreement with the Licensors.

On March 28, 2016, Solasia initiated a multi-center pivotal clinical trial intended to provide substantial evidence of efficacy necessary to support the filing of an application for an NDA for darinaparsin in certain of the territories assigned to Solasia. The initiation of the trial on March 28, 2016 triggered a $1.0 million milestone payment from Solasia to the Company which was received in May 2016. The Company subsequently made an equivalent payment to MD Anderson as the ultimate licensor of darinaparsin (see above).

Related Party Transactions

3 Months Ended

Mar. 31, 2019

Related Party Transactions

7. Related Party Transactions

Collaborations with Intrexon/ Precigen

During the three months ended March 31, 2018, the Company issued an aggregate of 3,624

shares of Series 1 preferred stock to Intrexon, the holder of all of the outstanding shares of the Company’s Series 1 preferred stock, as monthly dividend payments. At March 31, 2018, the Company recorded such shares of Series 1 preferred stock at a fair value of $

5.1

million which is a component of temporary equity. During the three months ended March 31, 2018, the Company recorded a gain on the change of the derivative liabilities in the amount of $28 thousand.

During the three months ended March 31, 2019, and 2018, the Company expensed $1.2 million and $2.8 million, respectively, for services performed by Precigen. As of March 31, 2019, and 2018, the Company recorded $0.9 million and $2.8 million, respectively, in current liabilities on its balance sheet for amounts due to Precigen.

discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replaced the terms of the Channel Agreement.

Collaboration with Precigen and MD Anderson

On January 13, 2015, the Company, together with Intrexon, entered into the MD Anderson License with MD Anderson (which Intrexon subsequently assigned to Precigen). Pursuant to the MD Anderson License, the Company, together with Precigen, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs, arising from the laboratory of Laurence Cooper, M.D., Ph.D., who became the Company’s Chief Executive Officer in May 2015 and was formerly a tenured professor of pediatrics at MD Anderson and is now currently a visiting scientist under that institution’s policies. In partial consideration for entering into the MD Anderson License, the Company issued MD Anderson an aggregate of

11,722,163

shares of common stock for which the Company incurred a

$67.3

million charge recorded in 2015.

The Company has determined that the rights acquired in the MD Anderson License represent in-process research and development with no alternative future use. During the three months ending March 31, 2018, the Company made one quarterly payment totaling

$2.7

million, bringing the total aggregate payments to

$41.9

million under this arrangement. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $26.4 million, of which $19.8 million is included in other current assets and the remaining $6.6 million is included in non-current assets at March 31, 2019. The classification is based on management’s current estimate of plans to utilize the prepaid balance and is subject to revision on a quarterly basis.

Settlement of a Related Party Relationship

Exclusive License Agreement with Precigen

On October 5, 2018,

the Company entered into the license agreement with Precigen. As between the Company and Precigen, the terms of the License Agreement replace the terms of: (a) the Channel Agreement, including all amendments to the Channel Agreement; (b) certain rights and obligations pursuant to the Ares Trading Agreement; (c) the MD Anderson License; and (d) the Research and Development Agreement, and any amendments or statements of work thereto.

gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products, (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) a second target, subject to the rights of Ares Trading (now Intrexon) to pursue such target under the Ares Trading Agreement, and (iii) TCR Products designed for neoantigens for the treatment of cancer. Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the

Sleeping Beauty

technology to research, develop and commercialize TCR Products.

The Company is solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products and after a two-year period, the TCR Products. Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize Gorilla IL-12 Products.

Ziopharm agreed to reimburse Precigen for certain historical costs of the licensed programs up to $1.0 million, payable quarterly. The Company determined that the fair value of this program was $1.0 million and this was expensed in accordance with ASC 730, Research and Development during the year ended December 31, 2018 and it has been included in accrued expense on the balance sheet.

The agreement also calls for an annual license fee of $100 thousand as long as the agreement is effective. The Company will also make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay Precigen tiered royalties ranging from low-single digit to high-single digit on the net sales derived from the sales of any approved IL-12 Products and CAR Products. The Company will also pay Precigen royalties ranging from low-single digit to mid-single digit on the net sales derived from the sales of any approved TCR Products, up to a maximum royalty amount of $100.0 million in the aggregate. The Company will also pay Precigen 20% of any sublicensing income received by the Company relating to the licensed products.

The Company is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. The Company and Precigen will share the development costs and operating profits for Gorilla IL-12 Products, with the Company responsible for 80% of the development costs and receiving 80% of the operating profits, and Precigen responsible for the remaining 20% of the development costs and receiving 20% of the operating profits.

Precigen will pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of Precigen’s CAR products, up to $50.0 million.

In consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 preferred stock held by or payable to Intrexon as of the date of the License Agreement. In addition, Precigen is required to transfer all of Ziopharm’s rights and obligations under the Ares Trading Agreement to Intrexon (or its affiliate). As a result, Ziopharm shall not be responsible for any remaining obligations under the Ares Trading Agreement.

The Company determined that this transaction represented a capital transaction between related parties. The Company calculated the fair value of the preferred stock and the derivative liability on the date of the transaction, noting a total fair value of $163.3 million. The relinquishment of the Company’s obligation under the Ares Trading Agreement was also considered part of the overall capital transaction. The Company recognized an additional credit to accumulated deficit of $49.5 million as a result of the relief of the obligation under the Ares Trading Agreement (Note 8). The total amount of the settlement was $212.8 million.

The Company incurred approximately $7.4 million of transaction advisory costs with third-party vendors, of which $5.4 million was considered a direct cost associated with the Series 1 preferred stock extinguishment and is also included as part of the consideration transferred. The remaining $2.0 million of transaction costs were recognized as an expense during the year ended December 31, 2018.

The Company recognized a net credit to accumulated deficit of $207.3 million, calculated as the difference in the carrying value of the Series 1 preferred stock, derivative liability, and contract liability, and the consideration transferred of $5.4 million, in connection with the transaction. This amount is included in net income available to common shareholders in the calculation of earnings per share (Note 3).

Leases

3 Months Ended

Mar. 31, 2019

Leases, Operating [Abstract]

Leases

8. Leases

The Company adopted Topic 842 on January 1, 2019 using the effective date method, in which it did not restate prior periods. Upon adoption, the Company elected the package of practical expedients permitted under the transition guidance within Topic 842 which, among other things, allowed it to carry forward the historical lease classification. The Company does not allocate consideration in its leases to lease and non-lease components and does not record leases on its balance sheets with terms of 12 months or less.

The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments. The Company’s incremental borrowing rate represents the rate of interest that it would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company considers publicly available data for instruments with similar terms and characteristics when determining its incremental borrowing rates.

The adoption of Topic 842 resulted in recognition of approximately $1.6 million of right-of-use assets and $1.6 million of lease liabilities on the Company’s balance sheets. The adoption did not have a material impact on the Company’s statements of operations or accumulated deficit. The Company has implemented changes to related processes, controls and disclosures in connection with the adoption of Topic 842.

The Company will review the classification of newly entered leases as either an operating or a finance lease and recognize a related right-of-use asset and lease liabilities on its balance sheets upon commencement.

In June 2012, the Company entered into a master lease for the Company’s corporate headquarters in Boston office, which was originally set to expire in August 2016. On December 21, 2015 and April 15, 2016, the Company renewed the sublease for the Company’s corporate headquarters, through August 31, 2021. As of March 31, 2019 and 2018, a total security deposit of $128 thousand is included in deposits on the balance sheet.

On January 30, 2018, the Company entered into a lease agreement for office space in Houston at MD Anderson. Under the terms of the Houston lease agreement, the Company leases approximately two hundred and ten square feet and are required to make rental payments at an average monthly rate of approximately $1 thousand through April 2021. All future rent expense incurred in Houston, will be deducted from the Company’s prepayments at MD Anderson.

On March 12, 2019, the Company entered into a lease agreement for office space in Houston. Under the terms of the Houston lease agreement, the Company leases approximately one thousand and thirty-eight square feet and is required to make rental payments at an average monthly rate of approximately $2 thousand through April 2021. As of March 31, 2019, a total security deposit of $2 thousand is included in deposits on the balance sheet.

The components of lease expense were as follows:

(in thousands)	Three Months Ended March 31, 2019
Operating lease cost	$	178
Total lease cost	$	178
Weighted-average remaining lease term (years)		2.40
Weighted-average discount rate		8.00	%

Cash paid for amounts included in the measurement of the lease liabilities were $178 thousand for the quarter ended March 31, 2019.

As of March 31, 2019, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

Maturity of Lease Liabilities	Operating Leases
2019 (excluding the three months ended March 31, 2019)		557
2020		755
2021		491
Total lease payments		1,803
Less: Imputed Interest		211
Present value of lease payments	$	1,592

Disclosures related to periods prior to adoption of the New Lease Standard

Prior to the adoption of ASC 842, the Company recorded rent expense on a straight-line basis over the term of the lease under ASC 840. Total rent expense for the three months ended March 31, 2018 was approximately $178 thousand.

For comparative purposes, the Company’s aggregate future minimum non-cancellable commitments under operating leases as of December 31, 2018 were as follows:

2019		723
2020		736
2021		488
Future minimum lease payments, net	$	1,947

Stock-Based Compensation

3 Months Ended

Mar. 31, 2019

Text Block [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:

	For the three months ended March 31,
(in thousands)	2019		2018
Research and development	$	433	$	603
General and administrative		1,023		3,056
Stock-based compensation expense	$	1,456	$	3,659

The Company granted an aggregate of 1,496,333 stock options during the three months ended March 31, 2019 with a weighted-average grant date fair value of $1.62 per share. The Company granted an aggregate of 7,500 stock options during the three months ended March 31, 2018 with a weighted-average grant date fair value of $3.00 per share.

The Company recognizes

forfeitures

as they occur.

For the three months ended March 31, 2019 and 2018, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:

	For the three months ended March 31,
	2019	2018
Risk-free interest rate	2.28 - 2.53%	2.56 - 2.74%
Expected life in years	6 - 6.25	6
Expected volatility	78.87 - 85.00%	80.75 - 81.10%
Expected dividend yield	0	0

Stock option activity under the Company’s stock option plan for the three months ended March 31, 2019 is as follows:

(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2018		5,277,085		$	4.24
Granted		1,496,333			2.24
Exercised		—			—
Cancelled		(1,357,333	)		4.33
Outstanding, March 31, 2019		5,416,085		$	3.66		7.82	$	5,494
Options exercisable, March 31, 2019		2,213,008		$	5.14		5.33	$	1,025
Options exercisable, December 31, 2018		3,099,935		$	5.15		4.93	$	88
Options available for future grant		3,996,638

At March 31, 2019, total unrecognized compensation costs related to unvested stock options outstanding amounted to $6.2 million. The cost is expected to be recognized over a weighted-average period of 1.61 years.

A summary of the status of unvested restricted stock for the three months ended March 31, 2019 is as follows:

	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2018		682,070		$	3.47
Granted		1,393,536			2.24
Vested		(446,428	)		2.24
Cancelled		(7,333	)		4.14
Non-vested, March 31, 2019		1,621,845		$	2.92

At March 31, 2019, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $4.1 million. The cost is expected to be recognized over a weighted-average period of 1.59 years.

Preferred Stock

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Preferred Stock

10. Preferred Stock

The Company’s Board of Directors is authorized to designate any series of Preferred Stock, to fix and determine the variations in relative rights, preferences, privileges and restrictions as between and among such series.

On June 29, 2016,

the Company entered into the 2016 ECP Amendment and Amendment to Exclusive Channel Collaboration Agreement, or the 2016 GvHD Amendment, with Intrexon (now Precigen) (Note 6). In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued to Intrexon

100,000 shares of its newly designated Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock had a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization. The Series 1 preferred stock had certain rights, preferences, privileges and obligations, including dividend rights, conversion rights, consent rights with respect to certain Company actions, and rights to preferential payments in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a change of control or sale, lease, transfer or exclusive license of all or substantially all of the Company’s assets prior to the conversion of the Series 1 preferred stock.

On October 5, 2018, the Company and Precigen entered into the License Agreement to replace all existing agreements between the companies, which provides the Company with certain exclusive and non-exclusive rights to technology controlled by Precigen. In consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 preferred stock held by or payable to Intrexon as of the date of the License Agreement (Notes 6 and 7).

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

11. Derivative Financial Instruments

The Company determined that certain embedded features related to the Series 1 preferred stock were derivative financial instruments. The company values the embedded derivative financial instruments related to the Series 1 preferred stock as Level 3 financial liabilities (Note 3).

On October 5, 2018, the Company entered into the License Agreement with Precigen. In partial consideration for the termination of the former agreements, the companies agreed that Intrexon would forfeit all outstanding shares of the Series 1 preferred stock held by Intrexon, including any accrued dividends (Note 10).

Warrants

3 Months Ended

Mar. 31, 2019

Warrants Disclosure [Abstract]

Warrant

12. Warrants

The Company assesses whether an equity classified financial instrument is indexed to an entity’s own stock for purposes of determining whether a financial instrument should be treated as a derivative.

In connection with the Company’s November 2018 private placement, the Company issued warrants to purchase an aggregate

of 18,939,394

shares of common stock which are exercisable six months after the closing of the private placement. The warrants have an exercise price

of $3.01 per share and have a five-year term. The relative fair value of the warrants was estimated at $18.4 million using a Black-Scholes model with the following assumptions: expected volatility of 71%, risk free interest rate of 2.99%, expected life of five years and no dividends.

The Company assessed whether the warrants require accounting as derivatives. The Company determined that the warrants were (1) indexed to the Company’s own stock and (2) classified in stockholders’ equity in accordance with Financial Accounting Standards Board (FASB”) Accounting Standards Codification (“ASC”) Topic 815,

Derivatives and Hedging

. As such, the Company has concluded the warrants meet the scope exception for determining whether the instruments require accounting as derivatives and should be classified in stockholders’ equity.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Leases

The adoption of Topic 842 resulted in recognition of approximately

$1.6

million of right-of-use assets and

$1.6

New Accounting Pronouncements

In November 2016, the FASB issued ASU 2016-18,

Statement of Cash Flows: Restricted Cash

		March 31,
	2019		2018
	(in thousands)
Cash and cash equivalents	$	51,487		$	51,108
Restricted cash included in prepaid expenses and other current assets		—			389
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	51,487		$	51,497

In August 2018, the FASB issued ASU No. 2018-13,

Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

In June 2018, the FASB issued ASU No. 2018-07,

Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows.

		March 31,
	2019		2018
	(in thousands)
Cash and cash equivalents	$	51,487		$	51,108
Restricted cash included in prepaid expenses and other current assets		—			389
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	51,487		$	51,497

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2019

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

Assets and liabilities measured at fair value on a recurring basis as of March 31, 2019 and December 31, 2018 were as follows:

($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of March 31, 2019		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	24,568	$	24,568	$	—	$	—

($ in thousands)			Fair Value Measurements at Reporting Date Using
Description	Balance as of December 31, 2018		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	24,437	$	24,437	$	—	$	—

Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share

Such potentially dilutive shares of common stock at March 31, 2019 and 2018 consisted of the following:

	March 31,
	2019		2018
Stock options		5,416,085		3,822,968
Unvested restricted stock		1,621,845		1,532,201
Warrants		18,939,394		—
Preferred stock		—		35,152,089
		25,977,324		40,507,258

Leases (Tables)

3 Months Ended

Mar. 31, 2019

Leases, Operating [Abstract]

Components of Lease Expense

The components of lease expense were as follows:

(in thousands)	Three Months Ended March 31, 2019
Operating lease cost	$	178
Total lease cost	$	178
Weighted-average remaining lease term (years)		2.40
Weighted-average discount rate		8.00	%

Lessee, Operating Lease, Liability, Maturity

As of March 31, 2019, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

Maturity of Lease Liabilities	Operating Leases
2019 (excluding the three months ended March 31, 2019)		557
2020		755
2021		491
Total lease payments		1,803
Less: Imputed Interest		211
Present value of lease payments	$	1,592

Future Net Minimum Lease Payments under Operating Leases

For comparative purposes, the Company’s aggregate future minimum non-cancellable commitments under operating leases as of December 31, 2018 were as follows:

2019		723
2020		736
2021		488
Future minimum lease payments, net	$	1,947

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Text Block [Abstract]

Stock-Based Compensation Expense on All Employee and Non-Employee Awards

The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:

	For the three months ended March 31,
(in thousands)	2019		2018
Research and development	$	433	$	603
General and administrative		1,023		3,056
Stock-based compensation expense	$	1,456	$	3,659

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model

For the three months ended March 31, 2019 and 2018, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:

	For the three months ended March 31,
	2019	2018
Risk-free interest rate	2.28 - 2.53%	2.56 - 2.74%
Expected life in years	6 - 6.25	6
Expected volatility	78.87 - 85.00%	80.75 - 81.10%
Expected dividend yield	0	0

Stock Option Activity under Stock Option Plan

Stock option activity under the Company’s stock option plan for the three months ended March 31, 2019 is as follows:

(in thousands, except share and per share data)	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, December 31, 2018		5,277,085		$	4.24
Granted		1,496,333			2.24
Exercised		—			—
Cancelled		(1,357,333	)		4.33
Outstanding, March 31, 2019		5,416,085		$	3.66		7.82	$	5,494
Options exercisable, March 31, 2019		2,213,008		$	5.14		5.33	$	1,025
Options exercisable, December 31, 2018		3,099,935		$	5.15		4.93	$	88
Options available for future grant		3,996,638

Summary of Unvested Restricted Stock

A summary of the status of unvested restricted stock for the three months ended March 31, 2019 is as follows:

	Number of Shares			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2018		682,070		$	3.47
Granted		1,393,536			2.24
Vested		(446,428	)		2.24
Cancelled		(7,333	)		4.14
Non-vested, March 31, 2019		1,621,845		$	2.92

Business - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 51,487	$ 61,729	$ 51,108
Accumulated deficit	(579,763)	$ (566,329)
Research and development expense related to joint venture	$ 35,000

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Total operating lease liabilities	$ 1,592
Operating Lease, Right-of-Use Asset	$ 1,589
Lessee, Operating Lease, Term of Contract	12 months
ASU 2016-02
Summary Of Significant Accounting Policies [Line Items]
Total operating lease liabilities	$ 1,600
Operating Lease, Right-of-Use Asset	$ 1,600

Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 51,487	$ 61,729	$ 51,108
Restricted cash included in prepaid expenses and other current assets			389
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 51,487	$ 61,729	$ 51,497	$ 71,335

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 24,568	$ 24,437
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 24,568	$ 24,437

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	25,977,324	40,507,258
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	18,939,394
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,416,085	3,822,968
Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,621,845	1,532,201
Series 1 Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		35,152,089

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Jan. 01, 2018	May 31, 2015
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	$ (579,763)	$ (566,329)
Difference between Revenue Guidance in Effect before and after Topic 606 \| ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit			$ (8,100)
ARES Trading License
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue, upfront payment				$ 57,500

Commitments and Contingencies - Additional Information (Detail) $ in Thousands					1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 05, 2018 USD ($)	Jan. 13, 2015 USD ($)	May 07, 2011 USD ($)	Mar. 07, 2011 USD ($)	Jul. 31, 2015 USD ($)	Aug. 24, 2004 Patent	Mar. 31, 2019 USD ($) shares	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017	Feb. 19, 2019 USD ($)	Jan. 30, 2018 ft²	Mar. 31, 2016 USD ($)	Dec. 31, 2014 USD ($)
Commitments and Contingencies Disclosure [Line Items]
Research and development expense							$ 9,476	$ 10,183	$ 1,000
Research and development arrangement Terms										Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. Under the License Agreement with Precigen, the Company and Precigen agreed that Precigen would no longer participate on the joint steering committee after the date of the License Agreement. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
Cash balance							51,487	51,108	$ 61,729
Agreement commencement date										2015-05
Reimbursement of historical costs	$ 1,000
MD Anderson License and the Research and Development Agreement Member [Member]
Commitments and Contingencies Disclosure [Line Items]
Research and development service agreement aggregate quarterly payments							1,400
Cash resources on hand							26,400
CRADA Agreement [Member]
Commitments and Contingencies Disclosure [Line Items]
Obligations due under contract											$ 5,000
Remaining contractual obligation											$ 6,900
Quarterly payments under contract							$ 625	625
Gorilla IL12 Products [Member] \| Parent [Member]
Commitments and Contingencies Disclosure [Line Items]
Percentage of development costs	80.00%
Percentage of operating profits	80.00%
CAR Products [Member]
Commitments and Contingencies Disclosure [Line Items]
Amount of royalties receivable	$ 50,000
The University of Texas MD Anderson Cancer Center and The Texas A & M University System
Commitments and Contingencies Disclosure [Line Items]
Milestone maximum payment														$ 4,500
Number of products \| Patent						2
Options to purchase common stock \| shares							50,222
The University of Texas MD Anderson Cancer Center and The Texas A & M University System \| Research and Development Expense
Commitments and Contingencies Disclosure [Line Items]
Issuance of common stock in a license agreement							$ 87
Solasia
Commitments and Contingencies Disclosure [Line Items]
Upfront payment received			$ 5,000	$ 5,000
Milestone payment received													$ 1,000
Milestone Payments Payable													$ 1,000
Solasia \| Development-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected Additional milestone payments to be received							32,500
Solasia \| Sales-based milestones
Commitments and Contingencies Disclosure [Line Items]
Expected Additional milestone payments to be received							$ 53,500
ARES Trading License
Commitments and Contingencies Disclosure [Line Items]
Research and development expense								$ 1,600
Agreement termination, notice period							90 days
Prepaid Expenses and Other Current Assets \| MD Anderson License
Commitments and Contingencies Disclosure [Line Items]
Cash balance							$ 19,800
Other Noncurrent Assets \| MD Anderson License and the Research and Development Agreement Member [Member]
Commitments and Contingencies Disclosure [Line Items]
Cash resources on hand							6,600
Other Noncurrent Assets \| MD Anderson License
Commitments and Contingencies Disclosure [Line Items]
Cash balance							$ 6,600
Intrexon Corporation
Commitments and Contingencies Disclosure [Line Items]
Licensing fee					$ 115,000
Milestone payment receivable period							2 years
Upfront payment received					$ 57,500
Percentage of upfront fee Payable					50.00%
Annual Licensing fee	100
Reimbursement of historical costs	1,000
Expected additional milestones payable	$ 52,500
Intrexon Corporation \| Gorilla IL12 Products [Member]
Commitments and Contingencies Disclosure [Line Items]
Percentage of development costs	20.00%
Percentage of operating profits	20.00%
Intrexon Corporation \| T-cell receptor
Commitments and Contingencies Disclosure [Line Items]
Maximum royalty amount	$ 100,000
Portion of income payable to related party	20.00%
Minimum \| MD Anderson License and the Research and Development Agreement Member [Member]
Commitments and Contingencies Disclosure [Line Items]
Research and development expense		$ 15,000
Maximum \| MD Anderson License and the Research and Development Agreement Member [Member]
Commitments and Contingencies Disclosure [Line Items]
Research and development expense		$ 20,000
Houston, TX
Commitments and Contingencies Disclosure [Line Items]
Operating lease area \| ft²												210

Related Party Transactions - Additional Information (Detail) - USD ($)			3 Months Ended		12 Months Ended
	Oct. 05, 2018	Jun. 29, 2016	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2015
Related Party Transaction [Line Items]
Change in fair value of derivative liability				$ 28,000
Amounts expensed for services incurred			$ 13,621,000	16,342,000
Research and development expense			9,476,000	10,183,000	$ 1,000,000
Aggregate Amount Potentially Reimburseable Amount	$ 1,000,000
Related Party Transaction Expenses From Transactions With Related Party Advisory Fees					$ 2,000,000
MD Anderson License and the Research and Development Agreement Member [Member]
Related Party Transaction [Line Items]
Research and development service agreement aggregate quarterly payments			1,400,000
Cash resources on hand			26,400,000
MD Anderson License and the Research and Development Agreement Member [Member] \| Other Current Assets [Member]
Related Party Transaction [Line Items]
Cash resources on hand			19,800,000
MD Anderson License and the Research and Development Agreement Member [Member] \| Other Noncurrent Assets [Member]
Related Party Transaction [Line Items]
Cash resources on hand			6,600,000
Gorilla IL-12 Products
Related Party Transaction [Line Items]
Percentage of development cost shared by other party	80.00%
Percentage of operating profit shared by other party	80.00%
Series 1 Preferred Stock
Related Party Transaction [Line Items]
Temporary equity, fair value				5,100,000
Change in fair value of derivative liability			(165,000)	28,000
Related Party Transaction Expenses From Transactions With Related Party Advisory Fees	$ 5,400,000
License Agreement \| M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)						11,722,163
Research and development expense						$ 67,300,000
Cooperative Research and Development Agreement \| M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Research and development service agreement aggregate quarterly payments				2,700,000
Research and development service agreement aggregate payments				41,900,000
Intrexon Corporation/Precigen
Related Party Transaction [Line Items]
Amounts expensed for services incurred			1,200,000	2,800,000
Amount due to related party, current			$ 900,000	$ 2,800,000
Aggregate Amount Potentially Reimburseable Amount	1,000,000
Annual License Fees	100,000
Additional Milestone Payment Payable For Licensed Program	52,500,000
Maximum Royalty payable	$ 100,000,000
Percentage Of Sublicensing Income	20.00%
Maximum Royalty Receivables	$ 50,000,000
Preferred Stock Contract Liability Derivative Liability	163,300,000
Increase in Accumulated Deficit	49,500,000
Related Party Transaction, Amounts of Transaction	$ 212,800,000
Intrexon Corporation/Precigen \| Gorilla IL-12 Products
Related Party Transaction [Line Items]
Percentage of development cost shared by other party	20.00%
Percentage of operating profit shared by other party	20.00%
Intrexon Corporation/Precigen \| Series 1 Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)		100,000		3,624
Consideration Transferred in License Agreement	$ 207,300,000
Preferred Stock Redemption Discount	5,400,000
Third Party Vendor [Member]
Related Party Transaction [Line Items]
Related Party Transaction Expenses From Transactions With Related Party Advisory Fees	$ 7,400,000

Lease expense (Detail) $ in Thousands	3 Months Ended
Lease expense (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
Operating lease cost	$ 178
Total lease cost	$ 178
Weighted-average remaining lease term (years)	2 years 4 months 24 days
Weighted-average discount rate	8.00%

Operating lease liabilities (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
2019 (excluding the three months ended March 31, 2019)	$ 557
2020	755
2021	491
Total lease payments	1,803
Less: Imputed Interest	211
Present value of lease payments	$ 1,592

Future minimum current and non-current lease liabilities (Detail) $ in Thousands	Dec. 31, 2018 USD ($)
2019	$ 723
2020	736
2021	488
Future minimum lease payments, net	$ 1,947

Leases - Additional Information (Details) $ in Thousands		3 Months Ended
Leases - Additional Information (Details) $ in Thousands	Mar. 12, 2019 USD ($) ft²	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Jan. 01, 2019 USD ($)	Jan. 30, 2018 USD ($) ft²
Land Subject to Ground Leases \| ft²	1,038
Lessee Operating Lease Monthly Average Rental Payment	$ 2
Operating Lease, Payments		$ 178
Operating Leases, Rent Expense, Net			$ 178
Security Deposit		2
Operating Lease, Right-of-Use Asset		1,589
Operating Lease, Liability		1,592
Boston, MA
Security Deposit		$ 128	$ 128
Sublease term amendment		Aug. 31, 2021
Operating lease expiration month and year		2016-08
Houston, TX
Operating Lease Area \| ft²					210
Operating Leases Future Minimum Monthly Payment Due Through Year 2021					$ 1
Adjustments for New Accounting Pronouncement [Member]
Operating Lease, Right-of-Use Asset				$ 1,600
Operating Lease, Liability				$ 1,600

Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,456	$ 3,659
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	433	603
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,023	$ 3,056

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	1,496,333	7,500
Weighted-average grant date fair value	$ 1.62	$ 3.00
Unvested Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested restricted stock outstanding	$ 6,200,000
Expected recognition period	1 year 7 months 9 days
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested restricted stock outstanding	$ 4,100,000
Expected recognition period	1 year 7 months 2 days

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Risk-free interest rate, Minimum	2.28%	2.56%
Risk-free interest rate, Maximum	2.53%	2.74%
Expected life in years		6 years
Expected volatility, Minimum	78.87%	80.75%
Expected volatility, Maximum	85.00%	81.10%
Expected dividend yield	0.00%	0.00%
Maximum [Member]
Expected life in years	6 years 3 months
Minimum [Member]
Expected life in years	6 years

Stock Option Activity Under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Number of Shares
Beginning Balance	5,277,085
Granted	1,496,333	7,500
Cancelled	(1,357,333)
Ending Balance	5,416,085		5,277,085
Options exercisable, at end of period	2,213,008		3,099,935
Options available for future grant	3,996,638
Weighted Average Exercise Price
Beginning Balance	$ 4.24
Granted	2.24
Cancelled	4.33
Ending Balance	3.66		$ 4.24
Options exercisable, at end of period	$ 5.14		$ 5.15
Weighted Average Contractual Term (Years)
Outstanding, at end of period	7 years 9 months 25 days
Options exercisable, at end of period	5 years 3 months 29 days		4 years 11 months 4 days
Aggregate Intrinsic Value
Outstanding, at end of period	$ 5,494
Options exercisable, at end of period	$ 1,025		$ 88

Summary of Non-Vested Restricted Stock (Detail) - Unvested Restricted Common Stock	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Number of Shares
Beginning Balance \| shares	682,070
Granted \| shares	1,393,536
Vested \| shares	(446,428)
Cancelled \| shares	(7,333)
Ending Balance \| shares	1,621,845
Weighted Average Grant Date Fair Value
Beginning Balance \| $ / shares	$ 3.47
Granted \| $ / shares	2.24
Vested \| $ / shares	2.24
Cancelled \| $ / shares	4.14
Ending Balance \| $ / shares	$ 2.92

Preferred Stock - Additional Information (Detail) - Intrexon Corporation/Precigen - Series 1 Preferred Stock - $ / shares		3 Months Ended
	Jun. 29, 2016	Mar. 31, 2018
Equity [Line Items]
Issuance of common stock in licensing agreement (in shares)	100,000	3,624
Preferred stock, stated value	$ 1,200

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fair Value Assumptions Expected volatility Rate Maximum	85.00%	81.10%
Fair Value Assumptions Risk Free Interest Rate Maximum	2.53%	2.74%
Fair Value Assumptions Expected Term1		6 years
Fair Value Assumptions Expected Dividend Rate	0.00%	0.00%
Private Placement [Member]
Number of securities into which the class of warrant converted	18,939,394
Warrant Exercise Per share	$ 3.01
fair value of adjustment of warrants	$ 18.4
Fair Value Assumptions Expected volatility Rate Maximum	71.00%
Fair Value Assumptions Risk Free Interest Rate Maximum	2.99%
Fair Value Assumptions Expected Term1	5 years
Fair Value Assumptions Expected Dividend Rate	0.00%